Adaptive Biotechnologies (ADPT) vs Scholar Rock (SRRK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adaptive Biotechnologies (ADPT) has outperformed Scholar Rock (SRRK) over the past year, gaining 83.1% versus a gain of 6.8%. Over five years, SRRK leads with a +54.7% price change compared with -21.6% for ADPT. Scholar Rock is the larger company by market cap ($5.14 billion vs $4.16 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | SRRK |
|---|---|---|
| Share price | $26.09 | $42.20 |
| Market cap | $4.16B | $5.14B |
| 1-day change | -0.72% | 0.00% |
| YTD return | +61.82% | -4.20% |
| 1-year return | +83.14% | +6.84% |
| 5-year return | -21.55% | +54.75% |
| EPS (TTM) | $-0.41 | $-3.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $0 |
| Revenue growth (YoY) | +54.77% | — |
| Net income (latest FY) | $-59.50M | $-377.94M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | — |
| Net margin | -21.48% | — |
| 52-week high | $30.74 | $61.76 |
| 52-week low | $12.00 | $27.07 |
| Distance from 52-week high | -15.13% | -31.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +8.51% | +66.92% |
| Average volume | 2.38M | 1.49M |
| Shares outstanding | 159.60M | 121.79M |
| Employees | 624 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADPT has outperformed SRRK by 76.3 percentage points over the past year.
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Scholar Rock
SRRK stock →Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees
ADPT vs SRRK FAQ
Which is bigger, Adaptive Biotechnologies or Scholar Rock?
Scholar Rock (SRRK) is larger, with a market capitalization of $5.14B compared with $4.16B for Adaptive Biotechnologies (ADPT).
Which stock has performed better over the past year, ADPT or SRRK?
ADPT returned +83.14% over the past 12 months, compared with +6.84% for SRRK (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Scholar Rock in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.